Analysis of Copy Number Variation in Urine: c-Myc Evaluation Using a Real-Time PCR Approach.
Copy number
Prostate cancer
Urine
c-Myc
Journal
Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969
Informations de publication
Date de publication:
2021
2021
Historique:
entrez:
2
3
2021
pubmed:
3
3
2021
medline:
7
4
2021
Statut:
ppublish
Résumé
Urine cell-free DNA has been shown as an informative noninvasive source of biomarkers for a number of diseases, especially for urological cancers. Starting from the hypothesis that the gain of c-Myc gene is a frequent aberration in several cancer types, including prostate cancer, we analyzed c-Myc copy number variation in urine, studying a little case series of prostate cancer patients, to test its feasibility. Here we report a general protocol that may be considered to analyze gene copy number variation in the urine cell-free fraction.
Identifiants
pubmed: 33651351
doi: 10.1007/978-1-0716-1354-2_5
doi:
Substances chimiques
Biomarkers, Tumor
0
Cell-Free Nucleic Acids
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
49-56Références
Sun J, Liu W, Adams TS et al (2007) DNA copy number alterations in prostate cancers: a combined analysis of published CGH studies. Prostate 67(7):692–700
doi: 10.1002/pros.20543
Fromont G, Godet J, Peyret A, Irani J, Celhay O, Rozet F, Cathelineau X, Cussenot O (2013) 8q24 amplification is associated with Myc expression and prostate cancer progression and is an independent predictor of recurrence after radical prostatectomy. Hum Pathol 44(8):1617–1623
doi: 10.1016/j.humpath.2013.01.012
Zhou K, Xu D, Cao Y, Wang J, Yang Y, Huang M (2014) C-MYC aberrations as prognostic factors in diffuse large B-cell lymphoma: a meta-analysis of epidemiological studies. PLoS One 9(4):e95020
doi: 10.1371/journal.pone.0095020
Watters AD, Latif Z, Forsyth A, Dunn I, Underwood MA, Grigor KM, Bartlett JM (2002) Genetic aberrations of c-myc and CCND1 in the development of invasive bladder cancer. Br J Cancer 87(6):654–658
doi: 10.1038/sj.bjc.6600531
Deming S, Nass S, Dickson R et al (2000) C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance. Br J Cancer 83:1688–1695
doi: 10.1054/bjoc.2000.1522
Salvi S, Gurioli G, De Giorgi U et al (2016) Cell-free DNA as a diagnostic marker for cancer: current insights. Onco Targets Ther 9:6549–6559
doi: 10.2147/OTT.S100901
Salvi S, Gurioli G, Martignano F et al (2015) Urine cell-free DNA integrity analysis for early detection of prostate cancer patients. Dis Markers 2015:574120
doi: 10.1155/2015/574120
Xia Y, Huang CC, Dittmar R et al (2016) Copy number variations in urine cell free DNA as biomarkers in advanced prostate cancer. Oncotarget 7(24):35818–35831
doi: 10.18632/oncotarget.9027
Cheng T, Jiang P, Teoh J, Heung M et al (2019) Noninvasive detection of bladder cancer by shallow-depth genome-wide bisulfite sequencing of urinary cell-free DNA for methylation and copy number profiling. Clin Chem 65(7):927–936
doi: 10.1373/clinchem.2018.301341
Satyal U, Srivastava A, Abbosh PH (2019) Urine biopsy-liquid gold for molecular detection and surveillance of bladder cancer. Front Oncol 9:1266
doi: 10.3389/fonc.2019.01266
Casadio V, Calistri D, Tebaldi M et al (2013) Urine cell-free DNA integrity as a marker for early bladder cancer diagnosis: preliminary data. Urol Oncol 31(8):1744–1750
doi: 10.1016/j.urolonc.2012.07.013
Salvi S, Casadio V (2019) Urinary cell-free DNA: potential and applications. Methods Mol Biol 1909:201–209
doi: 10.1007/978-1-4939-8973-7_15
Salvi S, Martignano F, Molinari C, Gurioli G, Calistri D, De Giorgi U, Conteduca V, Casadio V (2016) The potential use of urine cell free DNA as a marker for cancer. Expert Rev Mol Diagn 16(12):1283–1290
doi: 10.1080/14737159.2016.1254551